These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5 6
R Hui;  A Pearson; J Cortés; C Campbell; C Poirot; H A Azim; D Fumagalli; M Lambertini; F Daly; A Arahmani; J Pérez-Garcia; P Aftimos; P L Bedard; L Xuereb; E D Scheepers; M Vicente; T Goulioti; S Loibl; S Loi; M-J Pierrat; N C Turner; F Andre; G Curigliano;  2019

Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study

Clinical Cancer Research,  16 October 2019, online first, doi:10.1158/1078-0432.CCR-19-1164

E. de Azambuja;  N Ponde; M Procter; P Rastogi; R S Cecchini; M Lambertini; K Ballman; A Moreno-Aspitia; D Zardavas; L Roca; RD Gelber; M Piccart-Gebhart; T Suter;  11 October 2019

A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials

Breast Cancer Research and Treatment,  11 October 2019, online first: doi:10.1007/s10549-019-05453-z

M Procter; 

Simulation Study to Estimate Bias of Treatment Effect in Pain Scores in Diabetic Neuropathy

Pain Medicine,  24 August 2019, online first: doi:10.1093/pm/pnz192

C Kersten;  M G Cameron; A G Bailey; M T Fallon; B J Laird; V Paterson; R Mitchell; S M Fleetwood-Walker; F Daly; S Mjåland;  20 May 2019

Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial

Pain Medicine,  20 May 2019, online first: doi:10.1093/pm/pnz101

J F R Robertson;  Z Jiang; A Di Leo; S Ohno; K I Pritchard; M Ellis; I Bradbury; C Campbell;  May 2019

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

Breast Cancer,  11 May 2019, online first doi:10.1007/s12282-019-00973-4

W P Kirschbrown;  M Kågedal; B Wang; L Lindbom; A Knott; R Mack; S Monemi; I Nijem; S Girish; C Freeman; D Fumagalli; R McConnell; G Jerusalem; C Twelves; J Baselga; G von Minckwitz; J Bines; A Garg;  June 2019

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Cancer Chemotherapy and Pharmacology,  Volume 83, Issue No 6, pp. 1147-1158 doi:10.1007/s00280-019-03826-1

Rajiv Mallick;  Stephen Jolles; Hirokazu Kanegane; Dominique Agbor-Tarh; Mikhail Rojavin;  21 November 2018

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: A Pooled Analysis of Six Hizentra® Studies

Journal of Clinical Immunology,  1 - 12, doi:10.1007/s10875-018-0562-3

M Lambertini;  S Martel; C Campbell; S Guillaume; F Hilbers; U Schuehly; L Korde; H A Azim; S Di Cosimo; R C Tenglin; J Huober; J Baselga; A Moreno-Aspitia; M Piccart-Gebhart; RD Gelber; E. de Azambuja; M Ignatiadis;  Published online first 01 June 2018

Pregnancies during and following trastuzumab and/or lapatinib in patients with HER2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials in Cancer

Journal of Clinical Oncology,  Volume 36, No. 15, doi:10.1200/JCO.2018.36.15_suppl.10065

M Procter;  C Robertson;  Published online first 13 August 2018

Performance of Standard Imputation Methods for Missing Quality of Life Data as Covariate in Survival Analysis Based on Simulations from the International Breast Cancer Study Group Trials VI and VII

Communication in Statistics - Simulation and Computation,  Pages: 1-15, doi: 10.1080/03610918.2018.1473587

M Procter;  C Robertson;  Published online first 15 December 2017

Imputing Missing Quality of Life Data as Covariate in Survival Analysis of the International Breast Cancer Study Group Trials VI and VII

Communications in Statistics - Simulation and Computation,  Pages 1 - 11, doi:10.1080/03610918.2017.1390123

1 2 3 4 5 6